If a patient with T2D is considered to be at risk of hypoglycemia (e.g., glycated hemoglobin <7.0–8.0%, history of hypoglycemia, CKD, or advanced age), the dose of sulfonylurea could be reduced or even stopped, while the insulin dose could be reduced by 10–20% prior to SGLT-2i initiation, with the frequency of blood glucose monitoring increased [39,40,75]. The gene discussed is INS; the disease is Hypoglycemia.